GRML Greenland Mines Ltd
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907223 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-199.9%
TTM EPS YoY109.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-44.3%
ROA-44.0%
ROIC (approx.)-56.3%
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity0.00x
Current ratio62.16x
Interest coverage25.06x
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $409,521 | $400,536 | $321,271 | $124,342 | $273,305 | $238,700 | $0 | $0 |
| SG&A expense | $1.47M | $577,942 | $6.21M | $862,966 | $868,830 | $729,572 | $850,282 | $2.72M |
| Operating income | -$12.41M | -$5.49M | -$9.51M | -$1.81M | -$1.85M | -$1.89M | -$1.59M | -$1.85M |
| Interest expense | $4,950 | $4,888 | $1,615 | -$1.18M | $1.18M | $1.76M | $553,937 | $296,583 |
| Pretax income | -$13.64M | -$3.69M | -$13.86M | -$1.33M | -$2.90M | -$4.09M | -$2.12M | -$2.07M |
| Income tax | $0 | — | — | — | $0 | — | — | — |
| Net income | -$13.64M | -$3.69M | -$13.86M | -$1.33M | -$2.90M | -$3.76M | -$2.12M | -$2.07M |
| EBITDA | -$12.40M | — | — | — | -$1.85M | — | — | — |
| EPS (basic) | -2.51 | -0.03 | -0.15 | — | -2.39 | -0.12 | -0.08 | — |
| EPS (diluted) | -2.51 | -0.03 | -0.15 | — | -2.39 | -0.12 | -0.08 | — |
| Weighted avg. shares (diluted) | 5.44M | 126.52M | 93.73M | — | 1.21M | 33.95M | 27.52M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $57.39M | $9.30M | $10.00M | $7.18M | $7.35M | $8.43M | $565,869 | $63,741 |
| Receivables | — | — | — | — | $339,253 | — | — | — |
| Current assets | $59.46M | $12.21M | $10.93M | $7.29M | $7.77M | $8.55M | $687,712 | $157,811 |
| PP&E, net | $440,457 | $317,530 | — | $0 | — | — | — | — |
| Intangibles | $74.11M | $48.67M | $48.67M | $2.30M | — | — | — | — |
| Total assets | $137.69M | $65.01M | $59.74M | $9.59M | $10.07M | $10.85M | $2.99M | $2.46M |
| Current liabilities | $956,582 | $1.21M | $553,739 | $76,764 | $92,891 | $62,962 | $2.34M | $1.25M |
| Total liabilities | $1.35M | $7.11M | $8.27M | $129,764 | $145,891 | $195,409 | $2.35M | $1.27M |
| Shareholders' equity | $136.35M | $57.90M | $51.47M | $9.46M | $10.38M | $11.10M | $755,965 | $1.19M |
| Shares outstanding | 13.69M | 3.24M | 121.24M | 1.48M | 70.33M | 52.70M | 28.51M | 27.08M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.41M | -$6.85M | -$4.97M | -$1.28M | -$1.09M | -$1.97M | -$1.55M | -$944,154 |
| Capital expenditure | $133,915 | — | — | — | — | — | — | — |
| Free cash flow | -$10.54M | — | — | — | — | — | — | — |
| Investing cash flow | -$20.13M | -$428,680 | -$365,324 | — | — | — | — | $0 |
| Financing cash flow | $78.58M | $6.62M | $8.16M | $1.11M | $5,300 | $9.83M | $2.06M | $957,000 |
| Depreciation & amortization | $10,988 | — | — | — | $0 | — | — | — |
| Stock-based compensation | $907,375 | $111,083 | $5.11M | $39,931 | $639,586 | $390,195 | $495,500 | $659,207 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.